Decreased NAA in gray matter is correlated with decreased availability of acetate in white matter in postmortem multiple sclerosis cortex

Neurochemical Research

Volumn 38, Issue 11, 2013, Pages 2385-2396

  Li, S ^a   Clements, R ^a   Sulak, M ^a   Gregory, R ^a   Freeman, E ^a   McDonough, J ^a  

^a KENT STATE UNIVERSITY   (United States)

Author keywords

Acetate; Mitochondria; Multiple sclerosis; N acetyl aspartate

Indexed keywords

ACETIC ACID; ANTIMYCIN A1; N ACETYLASPARTIC ACID; UBIQUINOL CYTOCHROME C REDUCTASE; ASPARTIC ACID; N-ACETYLASPARTATE;

AMINO ACID BRAIN LEVEL; AMINO ACID SYNTHESIS; ARTICLE; AUTOPSY; CELL ACTIVITY; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAY MATTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOCHONDRION; MOTOR CORTEX; MULTIPLE SCLEROSIS; NEUROBLASTOMA CELL; PARIETAL CORTEX; PRIORITY JOURNAL; RESPIROMETRY; WHITE MATTER; ADULT; AGED; ANALOGS AND DERIVATIVES; DRUG EFFECTS; METABOLISM; MIDDLE AGED; MYELIN SHEATH; MYELINATED NERVE; NERVE CELL; NERVE FIBER; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMYCIN A; ASPARTIC ACID; AUTOPSY; AXONS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; MOTOR CORTEX; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE FIBERS, MYELINATED; NEURONS;

EID: 84886913148     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-1151-8     Document Type: Article

References (41)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938-952
2. England JD, Gamboni F, Levinson SR, Finger TE (1990) Changed distribution of sodium channels along demyelinated axons. Proc Natl Acad Sci U S A 87(17):6777-6780
3. Vukusic S, Confavreux C (2003) Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206(2):135-137
4. Moffett JR, Arun P, Ariyannur PS, Garbern JY, Jacobowitz DM, Namboodiri AM (2011) Extensive aspartoacylase expression in the rat central nervous system. Glia 59(10):1414-1434
5. Mehta V, Namboodiri MA (1995) N-acetyl aspartate as an acetyl source in the nervous system. Brain Res Mol Brain Res 31(1-2):151-157
6. Chakraborty G, Mekala P, Yahya D, Wu G, Ledeen RW (2001) Intraneuronal N-acetyl aspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase. J Neurochem 78(4):736-745
7. Ledeen RW, Wang J, Wu G, Lu ZH, Chakraborty G, Meyenhofer M, Tyring SK, Matalon R (2006) Physiological role of N-acetyl aspartate: contribution to myelinogenesis. Adv Exp Med Biol 576:131-143 discussion 361-3
8. Bjartmar C, Kidd G, Mörk S, Rudick R, Trapp BD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl-aspartate in chronic multiple sclerosis patients. Ann Neurol 48:893-901
9. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, Matthews PM, Arnold DL (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58(1):65-70
10. Gonen O, Catalaa I, Babb JS, Ge Y, Mannon LJ, Kolson DL, Grossman RI (2000) Total brain N-acetyl aspartate: a new measure of disease load in MS. Neurology 54(1):15-19
11. Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O (2004) Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 21:1825-1829
12. Mathiesen HK, Jonsson A, Tscherning T, Hanson LG, Andresen J, Blinkenberg M, Paulson OB, Sorensen PS (2006) Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol 63(4):533-536
13. Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI (2004) Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 62(4):624-627
14. Cader S, Johansen-Berg H, Wylezinska M, Palace J, Behrens TE, Smith S, Matthews PM (2007) Discordant white matter N-acetyl aspartate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal pathology in multiple sclerosis. Neuroimage 36(1):19-27
15. Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 11(6):646-651
16. Ciccarelli O, Altmann DR, McLean MA, Wheeler-Kingshott CA, Wimpey K, Miller DH, Thompson AJ (2010) Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology 74(9):721-727
17. Bö L, Geurts JJ, Mörk SJ, van der Valk P (2006) Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl 183:48-50
18. Fisher E, Lee JC, Nakamura K, Rudick RA (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64(3):255-265
19. Kutzelnigg A, Faber-Rod JC, Bauer J, Lucchinetti CF, Sorensen PS, Laursen H, Stadelmann C, Brück W, Rauschka H, Schmidbauer M, Lassmann H (2007) Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 17(1):38-44
20. Liepert J, Mingers D, Heesen C, Bäumer T, Weiller C (2005) Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study. Mult Scler 11(3):316-321
21. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ, Rudick R, Mirnics K, Trapp BD (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478-489
22. Pandit A, Vadnal J, Houston S, Freeman E, McDonough J (2009) Impaired regulation of electron transport chain subunit genes by nuclear respiratory factor 2 in multiple sclerosis. J Neurol Sci 279:14-20
23. Broadwater L, Pandit A, Azzam S, Clements R, Vadnal J, Yong VW, Freeman EJ, Gregory RB, McDonough J (2011) Analysis of the mitochondrial proteome in multiple sclerosis cortex. BBA Mol Bas Dis 1812:630-641
24. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, Lassmann H, Turnbull DM, Mahad DJ (2011) Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 69(3):481-492
25. Witte ME, Nijland PG, Drexhage JA, Gerritsen W, Geerts D, van Het Hof B, Reijerkerk A, de Vries HE, van der Valk P, van Horssen J (2013) Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 125(2):231-243
26. Rhein V, Baysang G, Rao S, Meier F, Bonert A, Müller-Spahn F, Eckert A (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29(6-7):1063-1071
27. Bartelt U, Kattermann R (1985) Enzymatic determination of acetate in serum. J Clin Chem Clin Biochem 23(12):879-881
28. Noda M, Yamashita S, Takahashi N, Eto K, Shen LM, Izumi K, Daniel S, Tsubamoto Y, Nemoto T, Iino M, Kasai H, Sharp GW, Kadowaki T (2002) Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes. J Biol Chem 277(44):41817-41826
29. Clark JB (1998) N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 20(4-5):271-276
30. Signoretti S, Marmarou A, Tavazzi B, Lazzarino G, Beaumont A, Vagnozzi R (2001) N-acetyl aspartate reduction as a measure of injury severity and mitochondrial dysfunction following diffuse traumatic brain injury. J Neurotrauma 18(10):977-991
31. Ciccarelli O, Toosy AT, De Stefano N, Wheeler-Kingshott CA, Miller DH, Thompson AJ (2010) Assessing neuronal metabolism in vivo by modeling imaging measures. J Neurosci 30(45):15030-15033
32. Madhavarao CN, Arun P, Moffett JR, Szucs S, Surendran S, Matalon R, Garbern J, Hristova D, Johnson A, Jiang W, Namboodiri MA (2005) Defective N-acetyl aspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc Natl Acad Sci U S A 102(14):5221-5226
33. Kaul R, Gao GP, Balamurugan K, Matalon R (1993) Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 5(2):118-123
34. Cumings JN, Goodwin It (1968) Sphingolipids and phospholipids of myelin in multiple sclerosis. Lancet II:664-665
35. Gerstl B, Eng LF, Tavaststjerna MG, Smith JK, Kruse SL (1970) Lipids and proteins in multiple sclerosis white matter. J Neurochem 17:677-689
36. Clausen J, Hansen IB (1970) Myelin constituents of human central nervous system. Acta Neurol Scand 46:1-17
37. Husted CA, Matson GB, Adams DA, Goodin DS, Weiner MW (1994) In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging. Ann Neurol 36(2):239-241
38. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD (2006) Astrocytes promote myelination in response to electrical impulses. Neuron 49(6):823-832
39. Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM (2011) Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 365:2188-2197
40. Kooi EJ, Geurts JJ, van Horssen J, Bø L, van der Valk P (2009) Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. J Neuropathol Exp Neurol 68(9):1021-1028
41. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J (2010) Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10(5):411-418